$KTTA
Pasithea Therapeutics Corp.

2022 Q3 Form 10-Q Financial Statement

#000121390022048085 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $218.6K $13.58K $13.66K
YoY Change
Cost Of Revenue $86.47K $15.10K $12.94K
YoY Change
Gross Profit $132.1K -$1.520K $720.00
YoY Change
Gross Profit Margin 60.45% -11.19% 5.27%
Selling, General & Admin $3.224M $3.079M $2.405M
YoY Change 153.14% 322.91% 337.63%
% of Gross Profit 2439.75% 334063.89%
Research & Development $1.159M
YoY Change
% of Gross Profit 877.08%
Depreciation & Amortization $16.67K $10.79K $5.010K
YoY Change
% of Gross Profit 12.62% 695.83%
Operating Expenses $4.383M $3.079M $2.405M
YoY Change 244.14% 322.91% 337.63%
Operating Profit -$4.251M -$3.080M -$2.405M
YoY Change 233.76% 323.12% 337.5%
Interest Expense -$335.3K $421.7K $785.3K
YoY Change 32.79%
% of Operating Profit
Other Income/Expense, Net -$335.3K $421.7K $45.00K
YoY Change 32.79%
Pretax Income -$4.586M -$2.658M -$1.574M
YoY Change 200.51% 265.19% 186.43%
Income Tax
% Of Pretax Income
Net Earnings -$4.586M -$2.658M -$1.574M
YoY Change 200.51% 265.19% 186.43%
Net Earnings / Revenue -2097.88% -19574.36% -11524.45%
Basic Earnings Per Share -$0.17 -$0.11 -$0.01
Diluted Earnings Per Share -$0.17 -$0.11 -$68.42K
COMMON SHARES
Basic Shares Outstanding 26.70M shares 23.44M shares 23.01M shares
Diluted Shares Outstanding 26.55M shares 23.44M shares 23.01M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.40M $47.94M $50.32M
YoY Change 106.16% 8325.62% 4599.71%
Cash & Equivalents $42.40M $47.94M $50.32M
Short-Term Investments
Other Short-Term Assets $866.0K $79.60K $628.7K
YoY Change 84.83% -77.63% 806.1%
Inventory
Prepaid Expenses $1.205M $594.6K
Receivables
Other Receivables
Total Short-Term Assets $44.47M $48.61M $50.95M
YoY Change 111.42% 5156.96% 4368.78%
LONG-TERM ASSETS
Property, Plant & Equipment $340.5K $169.6K $128.6K
YoY Change 3873.3%
Goodwill $3.854M $3.833M
YoY Change
Intangibles $12.50K
YoY Change
Long-Term Investments
YoY Change
Other Assets $46.60K
YoY Change
Total Long-Term Assets $5.139M $4.413M $128.6K
YoY Change 59863.97%
TOTAL ASSETS
Total Short-Term Assets $44.47M $48.61M $50.95M
Total Long-Term Assets $5.139M $4.413M $128.6K
Total Assets $49.61M $53.03M $51.08M
YoY Change 135.75% 5634.21% 4380.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.256M $848.7K $433.7K
YoY Change 137.82% 86.66% 81.12%
Accrued Expenses $258.0K $101.4K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.514M $950.1K $433.7K
YoY Change 186.68% 108.96% 81.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.306M $604.1K $667.5K
YoY Change -67.68%
Total Long-Term Liabilities $1.306M $604.0K $667.5K
YoY Change -67.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.514M $950.1K $433.7K
Total Long-Term Liabilities $1.306M $604.0K $667.5K
Total Liabilities $2.819M $1.554M $1.101M
YoY Change -38.27% 241.81% 359.88%
SHAREHOLDERS EQUITY
Retained Earnings -$11.03M -$6.447M
YoY Change
Common Stock $18.04K $18.05K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.79M $51.47M $49.98M
YoY Change
Total Liabilities & Shareholders Equity $49.61M $53.03M $51.08M
YoY Change 135.75% 5634.21% 4380.07%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.586M -$2.658M -$1.574M
YoY Change 200.51% 265.19% 186.43%
Depreciation, Depletion And Amortization $16.67K $10.79K $5.010K
YoY Change
Cash From Operating Activities -$5.239M -$2.377M -$2.527M
YoY Change 855.19% 375.95% 561.9%
INVESTING ACTIVITIES
Capital Expenditures -$197.4K -$38.31K -$113.9K
YoY Change 2203.85%
Acquisitions
YoY Change
Other Investing Activities -$32.98K $77.06K
YoY Change
Cash From Investing Activities -$230.4K $38.75K -$113.9K
YoY Change 2588.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.239M -2.377M -2.527M
Cash From Investing Activities -230.4K 38.75K -113.9K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.469M -2.338M $0.00
YoY Change -127.35% 368.19%
FREE CASH FLOW
Cash From Operating Activities -$5.239M -$2.377M -$2.527M
Capital Expenditures -$197.4K -$38.31K -$113.9K
Free Cash Flow -$5.041M -$2.339M -$2.414M
YoY Change 833.78% 532.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
005-92867
dei Entity Registrant Name
EntityRegistrantName
PASITHEA THERAPEUTICS CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1591963
dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Lincoln Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33139
dei City Area Code
CityAreaCode
(702)
dei Local Phone Number
LocalPhoneNumber
514-4174
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
KTTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26698688 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47940075 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52966706 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
594613 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
333751 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
79595 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
48614283 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
53300457 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169559 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20124 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
410392 usd
CY2022Q2 us-gaap Goodwill
Goodwill
3833453 usd
CY2022Q2 us-gaap Assets
Assets
53027687 usd
CY2021Q4 us-gaap Assets
Assets
53320581 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
848694 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
447280 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101418 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
950112 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
447280 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
604048 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
358245 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
245803 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6447139 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1452800 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1554160 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1452800 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64059 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10561 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
45000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1900080 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
495000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
495000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26698688 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26698688 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23008371 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23008371 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
18053 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
17684 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57966672 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53627883 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2214505 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51473527 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51420501 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53027687 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53320581 usd
CY2022Q2 us-gaap Revenues
Revenues
13581 usd
us-gaap Revenues
Revenues
27239 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15101 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28038 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
-1520 usd
us-gaap Gross Profit
GrossProfit
-799 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3078574 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
727947 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5483832 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1277556 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3080094 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-727947 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5484631 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1277556 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-421700 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1206997 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-48985 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2315 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
421700 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1251997 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2658394 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-727947 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4232634 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1277556 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2658394 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-727947 usd
us-gaap Net Income Loss
NetIncomeLoss
-4232634 usd
us-gaap Net Income Loss
NetIncomeLoss
-1277556 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23444135 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8258371 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23226253 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8036073 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2658394 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-727947 usd
us-gaap Net Income Loss
NetIncomeLoss
-4232634 usd
us-gaap Net Income Loss
NetIncomeLoss
-1277556 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-53498 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2312 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2707379 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-730262 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4286132 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1279868 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
241355 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1208926 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-549609 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
900672 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
299665 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-2312 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-727947 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
470078 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51420501 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
135630 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-4513 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1574240 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
49977378 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
125586 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
433741 usd
CY2022Q2 ktta Stock Issued During Period Value Warrants Instrument Issued For Acquisition
StockIssuedDuringPeriodValueWarrantsInstrumentIssuedForAcquisition
350722 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
1208926 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1208926 usd
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
3293479 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax
OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
-48985 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2658394 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
51473527 usd
us-gaap Net Income Loss
NetIncomeLoss
-4232634 usd
us-gaap Net Income Loss
NetIncomeLoss
-1277556 usd
us-gaap Depreciation
Depreciation
15801 usd
us-gaap Share Based Compensation
ShareBasedCompensation
694957 usd
us-gaap Share Based Compensation
ShareBasedCompensation
299665 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
282860 usd
ktta Increase In Fair Value Of Warrant Liabilities
IncreaseInFairValueOfWarrantLiabilities
1206997 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
211482 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
68610 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
79595 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
99171 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
448078 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
16271 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4904508 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-881283 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
152177 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-77060 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75117 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-47006 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2312 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5026631 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
325331 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52966706 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
243650 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47940075 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
568981 usd
ktta Lease Liabilities Arising From Obtaining Rightofuse Assets
LeaseLiabilitiesArisingFromObtainingRightofuseAssets
410392 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
186331 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of fair value of the warrant liabilities. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21503 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16772 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1379 usd
CY2022Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
10787 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
15801 usd
CY2021Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
0 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
0 usd
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3445200 usd
CY2021Q3 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2137800 usd
CY2021Q3 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
1307400 usd
CY2022Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of June 30, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
ktta Payments In Advance
PaymentsInAdvance
1 pure
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.30 pure
CY2022Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2022Q2 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
1.214 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1
CY2021Q4 us-gaap Foreign Currency Exchange Rate Remeasurement1
ForeignCurrencyExchangeRateRemeasurement1
1.348 pure
CY2022Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.299 pure
CY2021Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.371 pure
CY2022Q2 ktta Foreign Currency Exchange Rate Remeasurements
ForeignCurrencyExchangeRateRemeasurements
1.045 pure
CY2021Q4 ktta Foreign Currency Exchange Rate Remeasurements
ForeignCurrencyExchangeRateRemeasurements
1.132 pure
CY2022Q2 ktta Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.087 pure
CY2021Q4 ktta Foreign Currency Exchange Rate Translation
ForeignCurrencyExchangeRateTranslation
1.143 pure
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
45000 usd
us-gaap Class Of Warrant Or Right Expense Or Revenue Recognized
ClassOfWarrantOrRightExpenseOrRevenueRecognized
Each Unit consisted of one share of Common Stock and one Public Warrant. Each redeemable Public Warrant entitles the holder to purchase one share of Common Stock at a price of $6.25 per share, will be exercisable upon issuance and will expire five years from issuance
CY2022Q1 us-gaap Lessee Finance Lease Description
LesseeFinanceLeaseDescription
The lease has a 60-month term, and the Company has an option to extend the term for one 5-year renewal period at the prevailing market rate that the landlord is then obtaining from tenants for comparable space in the building. The lease has a base monthly rent of $8,336 per month for the first 12 months, with the base monthly rent increasing by 4% on the first anniversary of the lease commencement date and every 12 months thereafter. In addition to the base monthly rent, commencing on the first anniversary of the lease commencement date, the Company will pay its share of certain direct operating and tax expenses incurred by the landlord in maintaining the building.
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
431000 usd
CY2022Q2 us-gaap General Fair Value Hedge Information Minimum R Square Percentage
GeneralFairValueHedgeInformationMinimumRSquarePercentage
0.078 pure
CY2021Q4 ktta Consultingagreementannualsalary
Consultingagreementannualsalary
120000 usd
CY2022Q2 us-gaap Excess Stock Shares Authorized
ExcessStockSharesAuthorized
500000000 shares
ktta Description Of Authorized Capital Stock
DescriptionOfAuthorizedCapitalStock
(i) 495,000,000 shares of common stock having a par value of $0.0001 per share and (ii) 5,000,000 shares of preferred stock having a par value of $0.0001 per share.
CY2021Q1 us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
1000000 usd
CY2021Q1 ktta Sale Of Stock Number Of Shares Issued In Transaction1
SaleOfStockNumberOfSharesIssuedInTransaction1
625000 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.6
ktta Shares Issued1
SharesIssued1
395625 shares
us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
633000 usd
CY2021Q4 ktta Cash Fee
CashFee
0.09 pure
CY2021Q4 ktta Accountable Expenses
AccountableExpenses
70000 usd
CY2021Q4 ktta Shares Per Shares
SharesPerShares
8680000 shares
CY2021Q4 ktta Purchase To Warrants
PurchaseToWarrants
8680000 shares
ktta Offering Price Per
OfferingPricePer
3.5
ktta Aggregate Gross Proceeds
AggregateGrossProceeds
30380000 usd
ktta Underwriter Discounts And Fees
UnderwriterDiscountsAndFees
27000000 usd
ktta Warrants Remain Outstanding
WarrantsRemainOutstanding
8680000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
600000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
400000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.69
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
100000 shares
ktta Weightedaverage Exercise Price Per Share Exercisable
WeightedaverageExercisePricePerShareExercisable
5
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
0 usd
CY2022Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
100000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
200000 usd
CY2021Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
300000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
300000 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
700000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.45
us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.404 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.032 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2021Q2 us-gaap Other General Expense
OtherGeneralExpense
15000 usd
us-gaap Other General Expense
OtherGeneralExpense
15000 usd
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1120000 shares
CY2021Q4 ktta Exercised Price Per Share
ExercisedPricePerShare
6.25
CY2021Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7000000 usd
ktta Fair Value Of Public Warrants
FairValueOfPublicWarrants
0.065
ktta Fair Value Of Representative Warrants
FairValueOfRepresentativeWarrants
0.031
CY2022Q2 us-gaap Reinsurance Retention Policy Reinsured Risk Percentage
ReinsuranceRetentionPolicyReinsuredRiskPercentage
1 pure
CY2022Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
3260870 shares
CY2022Q2 us-gaap Financial Instrument Subject To Mandatory Redemption Par Value Per Share
FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare
1.01
CY2022Q2 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
1000000 shares
CY2022Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.88
CY2022Q2 us-gaap Average Term Of Credit Risk Derivatives1
AverageTermOfCreditRiskDerivatives1
P5Y
CY2022Q2 us-gaap Additional Collateral Aggregate Fair Value
AdditionalCollateralAggregateFairValue
400000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46595 usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
77060 usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
49380 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
19551 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
3833453 usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
3979444 usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
335243 usd
CY2022Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
335243 usd
CY2022Q2 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
3644201 usd
us-gaap Acquisition Costs
AcquisitionCosts
311065 usd
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8036073 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8258371 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Depreciation
Depreciation
usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
usd
ktta Increase In Fair Value Of Warrant Liabilities
IncreaseInFairValueOfWarrantLiabilities
usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
ktta Lease Liabilities Arising From Obtaining Rightofuse Assets
LeaseLiabilitiesArisingFromObtainingRightofuseAssets
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
ktta Weightedaverage Exercise Price Per Share Expired
WeightedaverageExercisePricePerShareExpired
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001841330

Files In Submission

Name View Source Status
0001213900-22-048085-index-headers.html Edgar Link pending
0001213900-22-048085-index.html Edgar Link pending
0001213900-22-048085.txt Edgar Link pending
0001213900-22-048085-xbrl.zip Edgar Link pending
f10q0622ex2-01_pasithea.htm Edgar Link pending
f10q0622ex31-1_pasithea.htm Edgar Link pending
f10q0622ex31-2_pasithea.htm Edgar Link pending
f10q0622ex32-1_pasithea.htm Edgar Link pending
f10q0622ex32-2_pasithea.htm Edgar Link pending
f10q0622_pasitheatherap.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ktta-20220630.xsd Edgar Link pending
ktta-20220630_cal.xml Edgar Link unprocessable
ktta-20220630_def.xml Edgar Link unprocessable
f10q0622_pasitheatherap_htm.xml Edgar Link completed
ktta-20220630_lab.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ktta-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable